MEXICO: Montreal Toulouse Test With Eye Tracking in Intensive Care Unit to Evaluate Comprehension
Sponsor
University Hospital, Tours (Other)
Overall Status
Completed
CT.gov ID
NCT05078632
Collaborator
(none)
113
1
18.7
6.1
Study Details
Study Description
Brief Summary
Assessment of the level of oral comprehension of the intensive care patient is essential to improve their care because they have often troubles like delirium.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Assessment of the level of oral comprehension of the intensive care patient is essential to improve their care because they have often troubles like delirium.
Study Design
Study Type:
Observational
Actual Enrollment
:
113 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Montreal Toulouse 86 Test Modified to be Used With Eye Tracking: Test Automation and Eye Course in Healthy Volunteers and Intensive Care Patients
Actual Study Start Date
:
Mar 7, 2019
Actual Primary Completion Date
:
Sep 25, 2020
Actual Study Completion Date
:
Sep 25, 2020
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Healthy volunteers healthy volunteers |
Other: Montreal-Toulouse Test adapted in eye tracking
participant pass an eye tracking test to evaluate comprehension
|
| intensive care patient patient hospitalized in intensive care unit |
Other: Montreal-Toulouse Test adapted in eye tracking
participant pass an eye tracking test to evaluate comprehension
|
Outcome Measures
Primary Outcome Measures
- Establish eye tracking standards for the test [during hospitalization in intensive care]
fixation time measurement in the defined area of interest
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- French speaker, RASS (Richmond Agitation-sedation scale) between -1 and +1, agree for participation
Exclusion Criteria:
- neurovisual disorders
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Tours | Tours | France | 37000 |
Sponsors and Collaborators
- University Hospital, Tours
Investigators
- Principal Investigator: Laetitia BODET-CONTENTIN, MD-PhD, University Hospital of TOURS
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Tours
ClinicalTrials.gov Identifier:
NCT05078632
Other Study ID Numbers:
- DR190027-MEXICO
First Posted:
Oct 14, 2021
Last Update Posted:
Oct 14, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Tours